Achieve Life Sciences received an FDA Complete Response Letter for cytisinicline citing manufacturing and labeling issues. It plans to resubmit in the fourth quarter of 2026 and anticipates potential approval by the end of the second quarter of 2027.
QUIT · Achieve Life Sciences, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
AchieveRx reported cash, cash equivalents, and marketable securities of $201.5 million as of September 30, 2026. Cytisinicline’s NDA resubmission remains on track for the fourth quarter of 2026; third-quarter net loss was $12.1 million.
Achieve Life Sciences, Inc. appointed Benjamin Halladay as Chief Financial Officer and principal financial officer effective as of October 5, 2026, while Mark Oki stepped down from the same role effective as of October 5, 2026.